Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin

By Andius Patrik   Damm Ole   Holmäng Sten  

Scandinavian Journal of Urology and Nephrology, Vol. 38, Iss. 4, 2004-09 ,pp. : 285-290

Informa Healthcare

Access to resources Recommend Favorite

Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience

By Pansadoro V.   Emiliozzi P.   de Paula F.   Scarpone P.   Pansadoro A.   Sternberg C.N.  

Urology, Vol. 59, Iss. 2, 2002-02 ,pp. : 227-231

Elsevier

Access to resources Recommend Favorite

Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin

By Sarosdy M.F.   Manyak M.J.   Sagalowsky A.I.   Belldegrun A.   Benson M.C.   Bihrle W.   Carroll P.R.   Ellis W.J.   Hudson M.A.   Sharkey F.E.  

Urology, Vol. 51, Iss. 2, 1998-02 ,pp. : 226-231

Elsevier

Access to resources Recommend Favorite

Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder - 15 years outcome

By Baniel J.   Grauss D.   Engelstein D.   Sella A.  

Urology, Vol. 52, Iss. 5, 1998-11 ,pp. : 785-789

Elsevier

Access to resources Recommend Favorite

Definitive tumor resection and percutaneous bacille Calmette-Guerin for management of renal pelvic transitional cell carcinoma in solitary kidneys

By Vasavada S.P.   Streem S.B.   Novick A.C.  

Urology, Vol. 45, Iss. 3, 1995-03 ,pp. : 381-386

Elsevier

Access to resources Recommend Favorite